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Received August 6, 2014; accepted August 25, 2014AbstractBackground: Chronic kidney disease (CKD) is associated with cardiac hypertrophy that leads to increased cardiovascular morbidity and
mortality. To date, use of the renineangiotensinealdosterone system blockade has been the main treatment modality. However,
renineangiotensinealdosterone system blockade by the angiotensin converting enzyme inhibitors (ACEi) can only partially reverse the cardiac
hypertrophy without having a significant impact on all-cause mortality as evidenced by meta-analyses from clinical trials. It is imperative to
elucidate the molecular pathogenesis of CKD-related cardiomyopathy for potential targets in further treatment.
Methods: Male SpragueeDawley rats that underwent subtotal nephrectomy (SNX) rats were established as the CKD model. A hemodynamic
study was used to evaluate the left ventricle (LV) structural and functional alterations. We used proteomic techniques to profile the LV protein
changes among sham-operated rats, SNX rats, and SNX rats with 6 months of ACEi enalapril interventions. The differentially expressed proteins
were further annotated by functional and network analyses.
Results: As compared to the sham-operated rats, the SNX rats had 25 upregulated and 46 decreased protein expression. The top canonical pathways
identified by ingenuity pathway analysis for the CKD cardiomyopathy were mitochondrial dysfunction, oxidative phosphorylation, fatty acid
b oxidation, protein ubiquitination, and ketolysis. The most relevant functions extracted from these networks contained 27 and 23 focused proteins,
respectively. They were related to cellular assembly and organization, RNA posttranscriptional modification, and protein synthesis. After
ACEi intervention for 6 weeks, the residual canonical pathways identified by ingenuity pathway analysis that mediated the CKD-related cardio-
myopathy were mitochondrial dysfunction, ketolysis, phenylalanine degradation IV, and putrescine degradation III. There were decreased Sirt3
and SNRNP, and increased monoamine oxidase and SAHH expression in the LVof SNX rats that could not be reversed by the ACEi.
Conclusion: Our studies provide a repertoire of potential biomarkers related to cardiac hypertrophy in CKD. There are still residual disturbed
molecules/pathways despite ACEi intervention. Further studies are warranted to investigate these potential novel targets to alleviate CKD-related
cardiomyopathy.
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The prevalence of chronic kidney disease (CKD) is
expanding rapidly worldwide. Although enormous efforts have
been devoted to alleviate renal function deterioration, cardio-
vascular disease remains the main cause of morbidity and
mortality in this population.
Contrary to the multitude of randomized control trials
(RCTs) for cardiovascular diseases in the general population,
there are still limited studies specifically designed for CKD-
related cardiac dysfunctions.1 RCTs for cardiovascular dis-
eases often exclude renal impairment patients at the very
beginning of enrollment. Nevertheless, for the few RCTs of
renal diseases that have been reported, they seldom consid-
ered cardiovascular parameters as the composite end point
for analysis.2 Therefore, current treatment strategies toward
CKD-related cardiovascular disease have mainly been
derived from experience with nonrenal dysfunction patients.
It should be noted that besides the traditional cardiovascular
risk factors, there are specific uremia-related milieus that
contributed to the cardiovascular pathology. Without a
comprehensive understanding of the molecular signatures
and pathways, it would be impossible to develop specific
therapeutic interventions for this CKD-related cardiac
dysfunction.
Because CKD is well known for the uncontrolled activation
of renineangiotensinealdosterone system (RAAS), RAAS
blockade [e.g., ACE inhibitors (ACEi) by enalapril] has been
the mainstay cardiovascular treatment modality.3 However, a
recent Cochrane review of four RCTs that enrolled 2177 stage
1e3 nondiabetic CKD patients suggested that ACEi had no
impact on all-cause mortality.4 For those CKD 5 patients
under maintenance hemodialysis, the secondary analysis of
the RCT of HEMO (originally targeted toward dialysis dose
and membrane flux) also revealed that ACEi could not
significantly affect mortality or cardiovascular morbidity,5 and
even unexpectedly had a higher risk of heart failure hospi-
talization. When taking left ventricular mass (LVM) as the
surrogate marker, Dyadyk et al6 reported that ACEi (captopril
and enalapril) could only induce regression in 12e19% of
LVM in hypertensive CKD patients. Our previous 12-month
RCT with the ACEi ramipril also failed to render significant
regression of LVM in normotensive hemodialysis patients.7
Therefore, it is imperative to elucidate mechanisms beyond
RAAS that mediate the pathogenesis of uremic
cardiomyopathy.
Proteomic techniques have been adopted to investigate
cardiovascular biology.8 However, there is still scarce appli-
cation of these techniques to study CKD-related cardiomy-
opathy. In this study, we used advanced proteomic techniques
to unravel the molecular signatures of uremic-related cardio-
myopathy, and to search for the remaining pathological
pathway/molecules after RAAS blockade by ACEi treatment.
We endeavored to improve our incomplete understanding of
the pathophysiology of CKD-related cardiomyopathy and
explore the potential candidate targets for therapeutic
interventions.2. Methods2.1. Rat subtotal nephrectomy modelThis study was conducted according to the guidelines of
the Taipei Veterans General Hospital Committee on Animal
Care and Supply, Taipei, Taiwan. Male SpragueeDawley rats
(from National Laboratory Animal Center, Taipei, Taiwan)
(200e250 g) were housed in animal care facilities with living
conditions maintained as follows: 12-hour light/dark cycles,
temperature at 21C, and humidity at 70%. The rats were
randomly allocated into three groups: sham-operated (SO),
subtotal nephrectomy (SNX) with vehicle (corn oil), and SNX
with the ACEi enalapril (3 mg/kg/d). The rat SNX models
were established similar to that in previous studies by
removing one kidney and two-thirds of the remaining kidney
at two stages.9 The SO group received two-stage bilateral
renal decapsulation. After the surgical procedures were
completed, the rats were gavaged with either vehicle or ena-
lapril for 6 weeks. All rats were provided standard food
(containing 40 g protein and 0.6 g NaCl per 100 g) and tap
water ad libitum.2.2. Hemodynamic studyThe rats were anesthetized with intraperitoneal pentobar-
bital sodium (40 mg/kg body weight). During the procedure,
the rat's body temperature was maintained at 37C with a small
animal blanket. The neck was carefully dissected to isolate the
right carotid artery, through which a 1.9F conductance catheter
(Scisense FT212, Ontario, Canada) was introduced into the
ascending aorta. The systolic and diastolic blood pressures of
the rats were then recorded to represent the central blood
pressure.
Subsequently, the conductance catheter was advanced into
the left ventricle (LV) to obtain the left ventricle hemodynamic
parameters. The heart rate, LV end-systolic pressure, LV end-
diastolic pressure, LV end-systolic volume, and LV end-
diastolic volume were recorded. The systolic function are
indexed by ejection fraction, peak positive value of the time
derivative of LV pressure (dP/dtmin), and cardiac output, which
is derived from (stroke volume)  (heart rate). The diastolic
function parameters are represented by the peak negative value
of the time derivative of LV pressure (dP/dtmin) and iso-
volumetric relaxation constant (microseconds).2.3. Preparation of crude tissue extractsAfter the hemodynamic study, the rats were sacrificed via
an intraperitoneal injection of superdose sodium pentobarbital.
Each heart was harvested, perfused with phosphate-buffered
saline, and weighed, after which the left ventricles were
further dissected. For each rat, 100 mg of the left ventricle was
minced and treated with 500 mL of extraction buffer [0.5 M
Tris, pH 6.8, 0.1% sodium dodecyl sulfate (SDS)] containing
the complete protease inhibitor cocktail (Roche, Mannheim,
Germany) and PhosSTOP phosphatase inhibitor cocktail
Table 1
Characteristics and hemodynamic data of the sham-operated, subtotal nephrectomy þ vehicle, and subtotal nephrectomy þ enalapril rats.
Parameters Sham-operated (N ¼ 6) Subtotal nephrectomy þ Vehicle
(N ¼ 6)
Subtotal nephrectomy þ Enalapril
(N ¼ 6)
Body weight (g) 420 ± 35 390 ± 39 397 ± 42
Renal function indices
Blood urea nitrogen (mg/dL) 16.2 ± 1.4 45.3 ± 2.8* 36.2 ± 3.1*,**
Creatinine (mg/dL) 0.8 ± 0.0 1.4 ± 0.1* 1.2 ± 0.1*,**
Carotid systolic blood pressure (mmHg) 116.7 ± 12.5 168.5 ± 14.6* 132.4 ± 11.8*,**
Carotid diastolic blood pressure (mmHg) 76.8 ± 13.1 106.5 ± 11.7* 94.2 ± 12.4*,**
Heart weight/body weight (%) 0.27 ± 0.02 0.38 ± 0.02* 0.32 ± 0.01*
Heart rate (/min) 382 ± 21 373 ± 29 360 ± 23
Left ventricular systolic pressure (mmHg) 156.9 ± 11.3 177.4 ± 28.0* 148.6 ± 12.4**
Left ventricular end diastolic pressure (mmHg) 17.4 ± 2.3 16.1 ± 4.2 15.5 ± 0.8
Ejection fraction (%) 56.3 ± 11.9 52.0 ± 9.3 54.3 ± 10.4
Cardiac output (mL/min) 50.6 ± 4.5 53.4 ± 7.9 52.0 ± 6.6
dP/dtmax (mmHg/s) 8974 ± 436 8592 ± 1067 7810 ± 1198
dP/dtmin (mmHg/s) 6335 ± 575 5767 ± 900* 5986 ± 724*
,**
Isovolumetric relaxation time (ms) 14.3 ± 0.6 17.5 ± 1.3* 15.2 ± 0.8
Data are expressed as mean ± standard error.
*p < 0.05 compared to sham-operated rats.
**p < 0.05 compared to subtotal nephrectomy þ vehicle rats.
dP/dtmax ¼ maximum derivative of change in systolic pressure over time; dP/dtmin ¼ maximum derivative of change in diastolic pressure over time.
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and centrifuged at 20,630g for 30 minutes at 4C (Model
5922; Kubota Corp., Tokyo, Japan) to remove cell debris. The
supernatants were collected, and total protein concentrations
were determined using the protein assay rapid kit (Wako Pure
Chemical Industries, Osaka, Japan).2.4. SDS-polyacrylamide gel electrophoresis and in-gel
digestionRat left ventricular protein sampleswere fractionated by 10%
SDS-polyacrylamide gel electrophoresis, similar to a previously
described method.10 The gels were stained with CBB staining
solution (0.1% CCBG-250, 34% methanol, 17% ammonium
sulfate, and 3% O-phosphoric acid), and 50 mg of each protein
sample was loaded onto the gel in triplicate. The gel lanes were
cut into 10 fractions based on molecular weight, and the gel
slices were destained repeatedly in a solution of 25 mM
NH4HCO3 and 50% (v/v) acetonitrile (1:1). After drying in aFig. 1. Representative left ventricular pressure recordings of the sham-operated rats
treated with enalapril. Compared to sham-operated controls, the SNX rats have sig
enalapril treatment. SNX ¼ subtotal nephrectomy.Speed-Vac (concentrator 5301; Eppendorf AG, Hamburg, Ger-
many), the slices were incubated with 1% b-mercaptoethanol
and 25 mMNH4HCO3 for 20 minutes at room temperature. For
cysteine alkylation, an equal volume of 5% 4-vinylpyridine in
25 mM NH4HCO3 and 50% acetonitrile was added for 20 mi-
nutes. After soaking the slices in 1 mL 25mMNH4HCO3 for 10
minutes, the slices were dried in a Speed-Vac for 20 minutes.
Then, 200 ng of modified trypsin (Promega, Mannheim, Ger-
many) in 25 mM NH4HCO3 was added, and tryptic digestion
was performed at 37C overnight. The tryptic digest was
removed from the gel, dried in a Speed-Vac, and stored at20C
until further analysis. The tryptic peptides were resuspended in
20 mL 0.1% (v/v) formic acid immediately before use.2.5. Mass spectrometric analysisTryptic peptide samples were injected into a nanoflow
HPLC system (Agilent Technologies 1200 series; Agilent
Technologies, Waldbronn, Germany) coupled to an LTQ-, subtotal nephrectomy rats treated with vehicle, and subtotal nephrectomy rats
nificantly higher left ventricular systolic pressure, which could be lowered by
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electrospray ionization source (Thermo Electron, Waltham,
MA, USA). The tryptic peptides were separated on an Agilent
C18 column (100 mm  0.075 mm, particle size 3.5 mm).
Mobile-phase solvent A was prepared as 0.1% formic acid in
water, and solvent B as 0.1% formic acid in acetonitrile. The
peptides were eluted from the column with a linear gradient of
5e35% solution B for 90 minutes and 35e95% solution B for
10 minutes. The eluted peptides were ionized with a spray
voltage of 2 kV and then introduced into the mass spectrom-
eter (MS). MS data were obtained using the data-dependent
acquisition method (isolation width: 1.5 Da), in which one
full MS survey scan (m/z ¼ 200e2000) at a high resolution of
30,000 at full-width half maximum was followed by a tandem
mass spectrometry (MS/MS) scan of the six most intense ions
with 2þ and 3þ charge states. Fragment ions of each selected
precursors were generated by collision-induced dissociation
using helium gas with collision energy of 35 eV.2.6. Database searchingThe LC-MS/MS raw data were analyzed using the Xcalibur
2.0.7 SR1 software (Thermo Electron), processed by an in-
house server where the peptide sequences were identified
against the Universal Protein Resource Knowledgebase, a rat
protein database (UniProt; http://www.uniprot.org/) that con-
tains ion scans obtained from MS/MS data. The lists of
searching parameters were set as follows: peptide mass
tolerance of 1.0 Da; fragment ion tolerance of 1.5 Da, enzyme
designated as trypsin; one missed cleavage by trypsin was
allowed; oxidation on methionine (þ16 Da) was allowed as
variable modifications. Positive protein identification was
based on the following criteria for an assigned peptide as
Xcorr 2.2 for 2þ, and 3.75 for 3þ charged ions. A protein
was considered to be identified when at least two peptides
were matched with the above Xcorr scores. MS spectral counts
were normalized on the sum of the spectral counts per bio-
logical sample for quantitative analyses.2.7. Pathway analysisThe differentially expressed left ventricular proteins be-
tween SO and SNX þ vehicle, and those between
SNX þ vehicle and SNX þ enalapril were uploaded with their
corresponding Swiss-Prot accession numbers into the in-
genuity pathway analysis (Ingenuity Systems, www.ingenuity.
com) for networks and functional analyses.2.8. Western blottingFig. 2. Predominant canonical pathway identified by ingenuity pathway
analysis for the differentially expressed left ventricular proteins between
sham-operated rats and the subtotal nephrectomy rats treated with vehicle. The
top canonical pathways participated in the CKD cardiomyopathy were mito-
chondrial dysfunction, oxidative phosphorylation, fatty acid b oxidation,
protein ubiquitination, and ketolysis. CKD ¼ chronic kidney disease.Frozen left ventricle tissues were pulverized into a fine
powder under liquid nitrogen, dissolved in a lysis buffer
(9.5 M urea, 2% w/v CHAPS. 0.8% w/v Pharmalyte, pH 3e10
and 1% w/v DTT) containing protease inhibitors, and then
centrifuged at 20,630g for 10 minutes. The supernatant were
collected and the protein concentration determined by use of
the Bradford method (Bio-Rad, Hercules, California, USA).
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SDS-polyacrylamide gel electrophoresis, then transferred to
polyvinylidene difluoride membranes. After the membrane
was blocked with the blocking solution (5% skim milk), it was
incubated with the primary antibodies as SirtT3 (Cell
Signaling), SNRNP200 (Abnova), Monoamine Oxidase A and
SAHH (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at
4C overnight. The membrane was subsequently incubated
with peroxidase-conjugated secondary antibody. After
washing, the blots were visualized using the enhanced chem-
iluminescence method, and ImageJ software was used to
quantify the image signal.2.9. Statistical analysisData are expressed as mean ± SE. All statistical analyses
were conducted using SPSS, version 19.0 (SPSS Inc., Chi-
cago, IL, USA). Unpaired Student t test was conducted for
comparisons between groups, and analysis of variance wasTable 2
Ingenuity pathway analysis of the differentially expressed left ventricular proteins
sham-operated rats.
ID Molecules in networka
1 YACAA2, YACADM, YAFM, Akt, [ALDH2, YECHS1, estrogen recep
YETFA, YFHL1, YFHL2, Growth hormone, [GSTM1, YHBA1/HBA2,
hemoglobin, YHK2, YLAMA4, YLOC299282, YLONP1, [MAOA,
mitochondrial complex 1, YMT-CO2, YMT-ND1*, NADH2 dehydrogen
YNAMPT, [NDUFA2, YNDUFA4, YNDUFA11, [NDUFV1, [NDUFV
PDGF BB, [SERPINA3, YSERPINB6, [SERPINF1, YSIRT3, trypsin
2 ↑AHCY, Ap1, CD3, Ck2, ↓ENO3, ↓FABP3, ↓FKBP3, ↑GDI1, ↓GDI2
↑HBB*, Histone h3, ↓HNRNPA2B1, ↓HSPA8*, IgG, Insulin, ↓KIF5B
↓KPNA4, ↓MYO1C, NFkB (complex), p85 (pik3r), ↓PAFAH1B2, Pkc
↓PNPT1, ↓PRPF8, Ras, ↓RPL4, ↑RPLPO, ↑RSU1, snRNP, ↓SNRNP
Sos, ↓STXBP3, ↓TCP1, ↑TGFBI, ↓YWHAB
3 20s proteasome, 26s Proteasome, Actin, ↑ACTN2, Alpha Actinin,
Alpha catenin, Calcineurin protein(s), ↓CAP1, ↑CKMT2, ↑CPT1B*
↑CSRP3, ERK1/2, ↓EZR, F Actin, ↓HARS, Hsp27, Hsp70, ↑HSPB1
↑IDH1, ↓IDH2, ↑MVP, ↓OTUB1, ↑PACSIN2, Proteasome PA700/20
↓PSMA8, PSMB, ↑PSMB1, ↓PSMB6, ↓PSMB7, ↓PSMD6, ↑RDX,
Rho gdi, Rock, Ubiquitin, ↑VIM
4 ↓ADSL, ↓APOA1BP, BCAS2, ↓C21orf33, ↑CNDP2, ↑CRYZ, CYC1,
↑DNPEP, ↓ECI2, FAM21A/FAM21C, FKBP15, HERC5, ↓HINT2,
↓IDH3B, ↑ISOC1, KIAA0196, ↑KIAA1033, ↓MTHFD1, MTHFD1L,
↑MURC, PI4K2A, ↑PROSC, REXO4, TXNRD1, ↑TXNRD2, UBC,
↑UQCR10, UQCR11, UQCRB, UQCRC1, UQCRC2, UQCRFS1,
UQCRQ, VPS29, WASH1
5 8-Oxo-7-hydrodeoxyguanosine, ↓ACAT1, ↓APOBEC2, BAG4,
↓BCKDHB, beta-estradiol, Ces, ↓Ces1C*, ↑Ces1d, CPT1, ↓CPT2,
↑CPT1B*, EIF2AK1, ↑GC, HERC5, IL6, ↑Kng1/Kng1I1, ↑LUM, MA
neuroprotectin D1, ↓NID1, NLRP12, NR1I2, ↓OXCT1, PDYN, PHLDA
↓PMPCA, PRSS23, ↑Rrbp1, TM4SF1, TNF, TP53, triacylglycerol lipa
TXNRD1, UNG
6 ↓4732456N10Rik, ↓Adssl1, caspase, CBLB, Collagen type I, copper, D
ERK, ↓ESD, FBXO32, FSH, GAS6, GNRH, GRB2, GZMA, homocyste
HSPB6, Jnk, lipoxin A4, MAOB, MAPKAPK5, MERTK, MYBPC3,
↓MYH4, P2RX7, P38 MAPK, PDYN, ↑PGM5, PI3K (complex),
pyruvaldehyde, SERPINB2, ↑SERPINF1, sorbitol, ↓THOP1, Vegf
a Data in bold denote focus proteins that were successfully mapped in the Ingen
b A score of >2 was considered significant ( p < 0.01).used for comparisons among groups. A p value <0.05 was
considered statistically significant.
3. Results3.1. Biochemical and hemodynamic dataBlood and urine measurements for each SO,
SNX þ vehicle, and SNX þ ACEi rat were performed every 2
weeks to ensure a successful establishment of the animal
model and monitor treatment effects. As demonstrated in
Table 1, the SNX rats had significantly more impaired renal
function indexed by increased blood urea nitrogen and creat-
inine than the SO rats. However, 6 weeks of enalapril treat-
ment could partially improve the renal function. The SNX rats
had markedly higher carotid systolic and diastolic blood
pressure, and enalapril could lower the blood pressure. The
SNX fed with vehicle had a significant hypertrophic heart as
indicated by the increased heart weight/body weight ratio.in the subtotal nephrectomy rats treated with vehicle when compared with the
Scoreb Focus
molecule
Top diseases and functions
tor,
ase,
2,
61 27 Developmental disorder,
hereditary disorder,
metabolic disease
,
,
(s),
200,
49 23 Cellular assembly and organization,
RNA posttranscriptional
modification, protein synthesis
,
,
s,
40 20 Cancer, hematological disease,
cellular assembly and organization
30 16 Cellular function and maintenance,
posttranslational modification,
protein synthesis
O,
1,
se,
24 14 Gene expression, cell cycle,
cell death and survival
MD,
ine,
10 7 Free radical scavenging, cell death
and survival, cell-to-cell signaling
and interaction
uity Pathway Knowledge Base.
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diac hypertrophy.3.2. Cardiac structural and functional alterationFig. 1 illustrates the representative left ventricle blood pres-
sure signals acquired from control rats, SNX rats treated with
vehicle, and SNX rats treated with ACEi. Compared to SO
controls, SNX rats had significantly higher left ventricular sys-
tolic pressure, which could be lowered by enalapril treatment.
SNX rats demonstrated a similar heart rate and systolic
function (indexed by dP/dtmax, ejection fraction, and cardiac
output) when compared with sham controls (Table 1). How-
ever, there was impaired diastolic function as shown by the
decreased dP/dtmin and increased isovolumetric relaxation
time. Compared with SNX rats receiving vehicle dosing, AECi
treatment tended to improve diastolic function.3.3. Comparative proteomics and pathway analysisCompared to SO rats, SNX rats had 25 upregulated and 46
decreased protein expressions in the left ventricle. The top
canonical pathways that participated in CKD cardiomyopathy
were mitochondrial dysfunction, oxidative phosphorylation,
fatty acid b oxidation, protein ubiquitination, and ketolysis
(Fig. 2). From a total of nine overlapping networks generated
by ingenuity pathway analysis (Ingenuity Systems; www.
ingenuity.com), six had a score >10 (score 2 is significant;Fig. 3. Ingenuity pathway network 1 (score 61) and network 2 (score 49) based on t
rats and the subtotal nephrectomy rats treated with vehicle. Protein nodes with color
interacting proteins added from the Ingenuity database. Unbroken lines connectin
interactions.it represents the log of the probability that the network was
found by chance) (Table 2). The most relevant functions
extracted from these networks contained 27 and 23 focused
proteins, respectively (Fig. 3). They were related to cellular
assembly and organization, RNA posttranscriptional modifi-
cation, and protein synthesis (Table 2).
Compared to SO rats, SNX rats treated with enalapril for
with 6 weeks had 21 upregulated and 40 decreased protein
expressions in the left ventricle. The residual canonical path-
ways mediating the CKD-related cardiomyopathy were mito-
chondrial dysfunction, ketolysis, phenylalanine degradation
IV, and putrescine degradation III (Fig. 4). The most relevant
functions extracted from the top two networks contained 24
and 15 focused proteins, respectively (Fig. 5). They were
related to cellular assembly and organization, free radical
scavenging, and renal damage (Table 3). Compared to SO rats
for the most differentially expressed left ventricular proteins,
there was a markedly decreased sirt3 and SNRNP200, and
increased monoamine oxidase (MAO) and adenosylhomocys-
teinase (AHCY) for SNX rats treated with enalapril.3.4. Western blot analysisExpressions of Sirt3, SNRNP, MAO, and SAHH of the left
ventricles from SO, SNX þ vehicle, and SNX þ enalapril rats
were further validated by Western blot analysis (Fig. 6).
Concordant with the proteomic findings, there was decreased
expression of Sirt3 and SNRNP. However, there was alsohe differentially expressed left ventricular proteins between the sham-operated
ed background are the identified proteins. Nodes with clear background are the
g the proteins indicate direct interactions, and broken lines indicate indirect
Fig. 4. Predominant canonical pathway identified by ingenuity pathway
analysis for the differentially expressed left ventricular proteins between
subtotal nephrectomy rats treated with enalapril and the sham-operated rats.
The residual canonical pathways mediating the CKD-related cardiomyopathy
are mitochondrial dysfunction, ketolysis, phenylalanine degradation IV, and
putrescine degradation III. CKD ¼ chronic kidney disease.
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status, which could not be ameliorated by enalapril.
4. Discussion
In the present study, we used the CKD model of SNX rats
to investigate the alterations of left ventricular structure
function in renal impairment status, and to evaluate the ther-
apeutic effects of RAAS blockade by ACEi. We observed
preserved systolic function and impaired diastolic function in
SNX, which resembles the heart failure with preserved ejec-
tion fraction11 found in CKD patients. ACEi cannot fully
reverse the LV structural and functional derangements in
CKD. Proteomic analysis of the SNX left ventricle revealed
deranged functional pathways related to mitochondrial
dysfunction, fatty acid b oxidation, protein ubiquitination,
RNA posttranscriptional modification, and ketolysis. Again,
ACEi could not thoroughly correct these irregularities. We
observed markedly decreased sirt3 and SNRNP200, and
increased MAO and AHCY in the left ventricles of enalapril-
treated SNX rats, which could be promising candidates for
multiple-target therapy.4.1. SIRT3We observed decreased Sirt3 and NAMPT in the SNX heart,
which could not be reversed by ACEi. Sirtuins are class III
histones that necessitate nicotinamide adenine dinucleotide
(NAD) for their activity with deacetylases. Sirt3 governs the
substrate for myocardial energy utilization by activating en-
zymes implemented in tricarboxylic acid cycle, fatty acid b
oxidation, and ketogenesis. Therefore, Sirt3 played a pivotal
role in cardiac hypertrophy, a state that the substrate for
myocardial energy utilization switches from fatty acid b
oxidation to glycolysis. Sirt3 also exerts cardioprotective ef-
fects by activating the Foxo3a-dependent antioxidant defense
mechanism that scavenges cellular reactive oxygen species
(ROS) and prevents cardiac hypertrophy.12 NAMPT is a stress
and nutrient-responsive protein that participates in the
biosynthesis of NAD, which is responsible for the activity of
sirtuins. Exogenous NAD has been shown to activate AMP-
activated protein kinase, to rescue the heart from ATP deple-
tion, stimulate PGC1a, and block the cardiac hypertrophic
response.13 We speculate that identifying drugs or nutrients
(e.g., NAD supplementations) capable of increasing Sirt3
expression or activity might be an attractive strategy to
ameliorate CKD-related cardiomyopathy.144.2. SNRNP200In the SNX LV, we observed decreased expression of
SNRNP200 helicase and PRPF8, which are the major com-
ponents of spliceosome. The spliceosome is composed of five
small nuclear ribonucleoproteins and hundreds of proteins. It
plays a crucial role in alternative splicing of premessenger
RNAs by recognizing the intron/exon boundaries, catalyzing
the removal of introns, and joining of exons. Through
Fig. 5. Ingenuity pathway network 1 (score 61) and network 2 (score 33) based on the differentially expressed left ventricular proteins between subtotal ne-
phrectomy rats treated with enalapril and the sham-operated rats. Protein nodes with colored background are the identified proteins. Nodes with clear background
are the interacting proteins added from the Ingenuity database. Unbroken lines connecting the proteins indicate direct interactions, and broken lines indicate
indirect interactions.
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mRNAs are produced and subsequently translated into func-
tionally diverse protein isoforms from a single gene. Deranged
exon exclusion, intron retention, or the use of alternative splice
sites could significantly influence the protein structure, local-
ization, regulation, and function. Disturbed expression of U5
small nuclear ribonucleoprotein associated U5-200kD RNATable 3
Ingenuity pathway analysis of the differentially expressed left ventricular proteins
sham-operated rats.
ID Molecules in networka
1 ↑AHCY, ↑ALDH2, Ap1, CD3, [CPT1B*, YENO3, ERK1/2, YEZR, YFA
[GDI1, ↓GDI2, Growth hormone, ↑GSTM1, YHBB, Histone h3, ↓HSPA
↑HSPB1, Insulin, Jnk, ↓KIF5B, ↓LOC299282, ↓LONP1, ↑MAOA, ↓MT
↓MT-ND1, ↓MYO1C, ↓NAMPT, P38 MAPK, ↑PACSIN2, Pkc(s), Rho g
↑SERPINF1, ↓SIRT3, Sos, ↓STXBP3
2 ↓4732456N10Rik, ↓ACAT1, ↑AHCY, ↓C21orf33, ↑Ces1C, ↑Ces1d, CYC
DCP2, DSTYK, GRB2, ↓HINT2, ↓IDH3B, ↑ISOC1, ↓MTHFD1, NBEA
NEK8, NR1I2, ↓PMPCA, POMP, ↑PROSC, PSMA8, ↑PSMB1, REG1A,
RIOK3, ↓RPL4, RPL15, RPL7L1, TRIM9, UBC, ↑UQCR10, UQCR11,
UQCRB, UQCRFS1, UQCRQ
3 ↓Adssl1, ↓AFM, Akt, BAG4, beta-estradiol, ↑CKMT2, ↑CRYZ, DMD,
DNAJC3, ENaC, FBXO32, Fe2þ, HRAS, ↑HSPB1, HSPB6, HSPB8, HTR
IgG, IRAK2, KCND3, LAMP2, lipoxin A4, MTDH, ↓MYH4, NFkB (com
↓NID1, ↓OTUB1, ↓OXCT1, p85 (pik3r), PI3K (complex), PRSS23, RPL1
↑RPLPO, SERP1, sorbitol
4 ↓APOBEC2, BCAS2, CD2BP2, CRNKL1, ECD, EFTUD2, EIF4E2,
↓LAMA4, LSM4, NAA38, PLRG1, PPIH, PRPF3, PRPF4, PRPF6,
↓PRPF8, PRPF31, PRPF4B, RBM5, RNU4-1, RNU5A-1, SART1,
↓SERPINB6, SF3B4, SLU7, SMNDC1, SNRNP27, SNRNP40,
↓SNRNP200, SNRPE, SNRPG, TOE1, TP53, USP39, ↓YWHAB
a Data in bold denote focus proteins that were successfully mapped in the Ingen
b A score of >2 was considered significant ( p < 0.01).helicase could also cause cell cycle abnormalities.15 Alterna-
tive splicing of sarcomeric genes, ion channels, and cell
signaling proteins can lead to cardiomyopathies, arrhythmias,
and other pathologies.16 Based on the decreased expression of
components in spliceosome, further studies are warranted to
unravel the role of alternative splicing and RNA targets in the
pathogenesis of CKD cardiomyopathy.of subtotal nephrectomy rats treated with enalapril when compared with the
Scoreb Focus
molecule
Top diseases and functions
BP3,
8*,
-CO2,
di,
61 24 Cellular assembly and organization,
free radical scavenging, renal damage
1,
,
33 15 Cardiovascular disease, hereditary
disorder, neurological disease
1A,
plex),
4,
20 10 Cardiac necrosis/cell death, cardiovascular
system development and function,
cell death and survival
10 6 RNA posttranscriptional modification,
hereditary disorder, ophthalmic disease
uity Pathway Knowledge Base.
Fig. 6. Western blot validations of the differential expression of Sirt3, SNRNP200, MAO, and AHCY in the left ventricles of sham-operated rats, subtotal ne-
phrectomy rats treated with vehicle, and those treated with enalapril. Concordant with the proteomic findings, there were decreased Sirt3 and SNRNP and increased
MAO and SAHH expression in renal dysfunctional status, which could not be ameliorated by enalapril. AHCY ¼ adenosylhomocysteinase; MAO ¼ monoamine
oxidase.
226 Y.-P. Lin et al. / Journal of the Chinese Medical Association 78 (2015) 218e2284.3. MAOMAOs are the flavoenzymes located at the outer membrane
of mitochondria, which are the major sources of ROS in car-
diomyocytes.17 They are responsible for the oxidative deam-
ination of catecholamines, serotonin, and biogenic amines.
During the process of MAO-mediated deamination, the by-
product as aldehydes could be deleterious to the heart by
deactivating proteasomes and altering mitochondrial bio-
energetics.18 Therefore, there are intricate connections among
MAO activation, mitochondrial ROS formation, and mito-
chondrial dysfunction,19 all of which are involved in
myocardial degeneration in heart failure and aging.20
Remarkably, several transcriptomic or proteomic studies
have already identified upregulated MAO-A in experimental
rat heart failure models of volume overload,21 pressure over-
load,22 and myocardial infarction,23 and suppression of
myocardial MAO has displayed beneficial effects. In vitrostudies have shown that senescent cardiomyocytes exhibited
distinctly enhanced MAO-A activity, and cardiomyocytes
exposed to angiotensin II displayed marked MAO activation.24
Given that CKD is a status of enhanced RAAS activation re-
flected by increased angiotensin II25 and accelerated senes-
cence,26 and that CKD cardiomyopathy is the combination of
pressure and volume overloads,27 we think that MAO inhibi-
tion might be promising for alleviating cardiac pathologies.4.4. AHCYS-Adenosylhomocysteine hydrolase (AHCY) catalyzes the
hydrolysis of S-adenosylhomocysteine to homocysteine and
adenosine,28 which is the only source of homocysteine in
mammals. Increased AHCY expressions were detected in our
study, particularly in the SNX left ventricles that denote the
increased homocysteine generation in situ. Homocysteine
could induce endothelial dysfunction through the decreased
227Y.-P. Lin et al. / Journal of the Chinese Medical Association 78 (2015) 218e228bioavailability of nitric oxide and increased oxidative stress on
vasculature causing thrombosis liability. It could also injure
cardiomyocytes through the activation of p38 MAPK,
decreased expression of thioredoxin, and increased ROS pro-
duction, ultimately leading to impaired cardiomyocyte
contractility and apoptosis.29 Hyperhomocysteinemia is the
well-recognized risk factor for cardiovascular complications in
CKD.30 However, several RCTs aimed to decrease the blood
homocysteine level failed to render improved clinical out-
comes. We reasoned that lower blood homocysteine does not
necessarily reflect the real tissue concentration in CKD left
ventricles. It would be innovative to evaluate whether sup-
pressing AHCY activity would be beneficial to cardiac
hypertrophy.4.5. OthersSeveral other potential proteinsmaymerit further evaluation.
The SNX rats had an increased expression of MURC (muscle-
restricted coiled-coil protein), a member of the caveolin fam-
ily,31 which is the hypertrophy-regulated gene that increases
myocardial expression under pressure overload.32 It modulates
the rho/rock pathway, and induces cardiac dysfunction and
conduction disturbance. There is decreased FHL2 in the SNX
left ventricle in the present study. FHL2 functions to suppress
calcineurin signaling and NFAT (nuclear factor of activated T
cell) activation, and consequently inhibits pathological cardiac
growth.33 Actually, decreased FHL2 expression is also observed
in failing human hearts.34 Moreover, we also found decreased
FABP3 (heart-type fatty acid binding protein-3), which is a
cytosolic fatty acid shuttle that facilitates the movement of fatty
acids in cardiacmuscle. It reversibly binds andmoves fatty acids
from the plasma membrane into storage or to the mitochondria
for oxidation. Decreased FABP3 expression might hamper
cardiac fatty acid utilization and increase the dependence on
glucose as a substrate.
In conclusion, consistent with previous clinical reports, we
observed that simply using the RAAS blockade by ACEi could
not untangle the intricate pathways involved in CKD-related
cardiomyopathy in this animal study. Further comprehensive
investigations of these pathways and the renocardiac network
would facilitate the development of a multifaceted interven-
tion for clinical applications in the future.
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